Docking and homology modeling explain inhibition of the human vesicular glutamate transporters

As membrane transporter proteins, VGLUT1–3 mediate the uptake of glutamate into synaptic vesicles at presynaptic nerve terminals of excitatory neural cells. This function is crucial for exocytosis and the role of glutamate as the major excitatory neurotransmitter in the central nervous system. The t...

Full description

Saved in:
Bibliographic Details
Published in:Protein science Vol. 16; no. 9; pp. 1819 - 1829
Main Authors: Almqvist, Jonas, Huang, Yafei, Laaksonen, Aatto, Wang, Da‐Neng, Hovmöller, Sven
Format: Journal Article
Language:English
Published: Bristol Cold Spring Harbor Laboratory Press 01-09-2007
Wiley-Blackwell
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As membrane transporter proteins, VGLUT1–3 mediate the uptake of glutamate into synaptic vesicles at presynaptic nerve terminals of excitatory neural cells. This function is crucial for exocytosis and the role of glutamate as the major excitatory neurotransmitter in the central nervous system. The three transporters, sharing 76% amino acid sequence identity in humans, are highly homologous but differ in regional expression in the brain. Although little is known regarding their three‐dimensional structures, hydropathy analysis on these proteins predicts 12 transmembrane segments connected by loops, a topology similar to other members in the major facilitator superfamily, where VGLUT1–3 have been phylogenetically classified. In this work, we present a three‐dimensional model for the human VGLUT1 protein based on its distant bacterial homolog in the same superfamily, the glycerol‐3‐phosphate transporter from Escherichia coli. This structural model, stable during molecular dynamics simulations in phospholipid bilayers solvated by water, reveals amino acid residues that face its pore and are likely to affect substrate translocation. Docking of VGLUT1 substrates to this pore localizes two different binding sites, to which inhibitors also bind with an overall trend in binding affinity that is in agreement with previously published experimental data.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0961-8368
1469-896X
1469-896X
DOI:10.1110/ps.072944707